Longevity Health Holdings, Inc. has announced an update to its merger agreement with 20/20 Biolabs, Inc. Originally disclosed on April 11, 2025, the Agreement and Plan of Merger involves Longevity Health Holdings' subsidiary, Longevity Health Biomarkers, Inc., merging with 20/20 Biolabs, which will then continue as a wholly owned subsidiary of Longevity Health Holdings. On June 24, 2025, the involved parties amended the original agreement to extend the Due Diligence Contingency Deadline to July 8, 2025. If not further extended by mutual consent, the merger agreement will automatically terminate on that date.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。